title: Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu.
abstract: MDX-210 is a bispecific antibody (BsAb) that recognizes Fc gamma R1 on monocytes and macrophages and the cell surface product of the HER-2/neu oncogene, which is overexpressed on some breast and ovarian cancers. Clinical trials have demonstrated that treatment with MDX-210 is well tolerated and that MDX-210 is both immunologically and clinically active. Optimization of the dose and schedule of MDX-210 and development of combination treatments with cytokines that modulate immune effector cells will greatly enhance the efficacy of this novel BsAb construct for treatment of tumours that overexpress HER-2/neu. We envision that MDX-210 will be effective for treating patients with tumors that overexpress HER-2/neu, especially in the minimal disease setting.
authors.affiliation: Norris Cotton Cancer Center, Lebanon, NH, USA.
authors.forename: F H
authors.initials: FH
authors.lastname: Valone
authors.forename: P A
authors.initials: PA
authors.lastname: Kaufman
authors.forename: P M
authors.initials: PM
authors.lastname: Guyre
authors.forename: L D
authors.initials: LD
authors.lastname: Lewis
authors.forename: V
authors.initials: V
authors.lastname: Memoli
authors.forename: M S
authors.initials: MS
authors.lastname: Ernstoff
authors.forename: W
authors.initials: W
authors.lastname: Wells
authors.forename: R
authors.initials: R
authors.lastname: Barth
authors.forename: Y
authors.initials: Y
authors.lastname: Deo
authors.forename: J
authors.initials: J
authors.lastname: Fisher
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis; D018033:Antibodies, Bispecific / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000918:Antibody Specificity; D000920:Antibody-Dependent Cell Cytotoxicity; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D016207:Cytokines / Q000378:metabolism; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007116:Immunization, Passive; D009363:Neoplasm Proteins / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D011961:Receptors, Fc / Q000276:immunology; D017452:Receptors, IgG / Q000276:immunology*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D016207:Cytokines; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011961:Receptors, Fc; D017452:Receptors, IgG